阿托瓦斯塔丁通过调节炎症来改善小鼠和患者的肠道屏障功能来缓解动脉样硬化
Congguo Yin1, Lingfei Li2, Zheng Zhang3
1The Fourth School of Clinical Medicine, Zhejiang Chinese Medicine University, Hangzhou, China; Department of Neurology, Hangzhou First People's Hospital, Hangzhou, China.
International immunopharmacology
|July 23, 2025
概括
阿托瓦斯塔丁 (ATO) 通过改善肠道屏障功能和减少炎症来预防动脉样硬化. 这项研究表明,ATO是ATO.
科学领域:
- 心血管研究研究心血管研究
- 胃肠病学 胃肠病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 动脉样硬化 (AS) 是一种由高胆固醇驱动的慢性炎症性疾病,与胃肠道功能障碍有关.
- 阿托瓦斯塔丁 (ATO) 是一种降脂药,也影响肠道功能.
- 了解胃肠血管相互作用对于AS治疗至关重要.
研究的目的:
- 为了评估阿托瓦斯塔丁 (ATO) 对动脉样硬化的作用.
- 调查ATO如何影响AS中的胃肠血管相互作用.
主要方法:
- ApoE-/-小鼠被食高胆固醇饮食,并接受ATO或安慰剂治疗.
- 在实验室中对Caco-2细胞进行了透性测试.
- 临床研究涉及AS患者,AS接受ATO治疗,以及健康对照,评估动脉狭窄和血清标志物.
主要成果:
- 在小鼠中,ATO治疗显著降低了大动脉动脉样硬化,并改善了脂质谱.
- ATO降低了肠道透性,抑制了肠道免疫激活,降低了循环中的内毒素水平.
- 临床数据证实了ATO的降脂作用,并揭示了AS患者内毒素,炎症性细胞因子和ZO-1之间的相关性.
结论:
- 阿托瓦斯塔丁 (ATO) 显示出抗动脉样硬化作用,可能由增强的肠壁功能和抗炎作用介导.
- 这些发现突显了肠-血管轴在AS管理中的重要性,并提出了新的治疗途径.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
878
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
878
Cholesterol: Significance and Regulation
694
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
694
Atherosclerosis III: Management
36
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
36
Atherosclerosis I: Introduction
89
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
89
Inflammatory Bowel Disease IV: Pharmacological Management
196
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
196
Inflammation
55.2K
Overview
55.2K

